Uncategorized
VIDEO: ‘Exciting times’ for Ocular Therapeutix
SAN FRANCISCO — At the Ophthalmology Innovation Summit preceding the American Academy of Ophthalmology meeting, Antony Mattessich, CEO of Ocular Therapeutix, discusses Dextenza (dexamethasone ophthalmic insert 0.4 mg) as well as some of the company’s phase 1 programs.